TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31533854

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (12-week supervised training, 1 hour per day, 4 days per week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific exercise intervention, maintain original lifestyle)
Number of subjects: 120
Study: 30423680

Group type: EXPERIMENTAL
Intervention: Bledsoe Thruster brace
Number of subjects: 100

Group type: COMPARATOR
Intervention: SofTec OA brace
Number of subjects: 100
Study: 25350228

Group type: EXPERIMENTAL
Intervention: Laparoscopic pectopexy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Laparoscopic sacropexy
Number of subjects: 85
Study: 23690976

Group type: EXPERIMENTAL
Intervention: Resistance training (n=28)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Aerobic training (n=30)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Balance and tone (control group, n=28)
Number of subjects: 86
Study: 22166001

Group type: EXPERIMENTAL
Intervention: IPTc + HMM
Number of subjects: 1000

Group type: COMPARATOR
Intervention: HMM
Number of subjects: 1000
Study: 18541001

Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 60

Group type: COMPARATOR
Intervention: PC
Number of subjects: 60
Study: 16724169

Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin, 10 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-release tolterodine, 4 mg daily
Number of subjects: 0
Study: 12563548

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study: 10971469

Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9000925

Group type: EXPERIMENTAL
Intervention: Wound assessment chart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard documentation methods
Number of subjects: 0
Study: 1623653

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6206316

Group type: EXPERIMENTAL
Intervention: Indapamide (IND) 2.5 mg q am
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 50 mg q am
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30809631

Group type: EXPERIMENTAL
Intervention: Originator infliximab
Number of subjects: 2239

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 2239
Study: 30554233

Group type: EXPERIMENTAL
Intervention: 22‐oxa‐calcitriol (50,000 IU/week)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Calcitriol (50,000 IU/week)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Lactose powder (placebo)
Number of subjects: 369
Study: 26879816

Group type: EXPERIMENTAL
Intervention: Artemisinin conventional formulation (160 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Artemisinin conventional formulation (500 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Artemisinin micronized formulation (160 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Artemisinin micronized formulation (160 mg) with piperaquine phosphate (360 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increasing dose of artemisinin
Number of subjects: 15
Study: 24460845

Group type: EXPERIMENTAL
Intervention: Usual care plus the NHS Direct Healthlines Service (intervention group)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1200
Study: 22231705

Group type: EXPERIMENTAL
Intervention: UDCA combined with Tongdan Decoction
Number of subjects: 60

Group type: COMPARATOR
Intervention: UDCA alone (Control)
Number of subjects: 60
Study: 19665340

Group type: EXPERIMENTAL
Intervention: Counselling with a decision aid (DA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine counselling
Number of subjects: 0
Study: 17980418

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: T2206C SNP
Number of subjects: 311
Study: 14700510

Group type: EXPERIMENTAL
Intervention: Combination therapy (amlodipine 5 mg + benazepril 20 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Benazepril (40 mg)
Number of subjects: 106
Study: 12473867

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: valsartan vs HCTZ
Number of subjects: 60

Group type: COMPARATOR
Intervention: valsartan vs placebo
Number of subjects: 60
Study: 9440779

Group type: EXPERIMENTAL
Intervention: Immunotherapy using standardized D. farinae antigen
Number of subjects: 60
Study: 2776953

Group type: EXPERIMENTAL
Intervention: Intracervical gel containing 50 mg 17 beta‐oestradiol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 28
Study: 768851

Group type: EXPERIMENTAL
Intervention: L-asparaginase 100 U/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-asparaginase 500 U/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-asparaginase 1500 U/kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: L-asparaginase (all doses)
Number of subjects: 22
Study: 31027915

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 402

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 402
Study: 28092401

Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric carboxymaltose)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Oral iron (ferrous sulphate)
Number of subjects: 116
Study: 25720104

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (continuous negative pressure of -80 mmHg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional dressings (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 80
Study: 23390123

Group type: EXPERIMENTAL
Intervention: DDD pacing at 60 ppm
Number of subjects: 101

Group type: COMPARATOR
Intervention: DDI pacing at 30 ppm
Number of subjects: 101
Study: 21086117

Group type: EXPERIMENTAL
Intervention: Zolpidem (Zp) 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zopiclone (Zc) 7.5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19940299

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 16963343

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with fiber-rich whole-grain cereals plus exercise
Number of subjects: 134

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 134
Study: 14599046

Group type: EXPERIMENTAL
Intervention: GOS/FOS mixture
Number of subjects: 90
Study: 10889149

Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxicillin, and clarithromycin (OAC) for 1 week; n = 295
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo; n = 292
Number of subjects: 587
Study: 8737958

Group type: EXPERIMENTAL
Intervention: trimetazidine 20 mg tid
Number of subjects: 149

Group type: COMPARATOR
Intervention: propranolol 40 mg tid
Number of subjects: 149
Study: 1568427

Group type: EXPERIMENTAL
Intervention: Steroid electrode (0.5 mg dexamethasone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Electrode without steroid
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Steroid electrode
Number of subjects: 20
Study: 2860153

Group type: EXPERIMENTAL
Intervention: Intraperitoneal irrigation with low molecular weight povidone-iodine solution (PVP-I LMW)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline irrigation (Control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Serum iodine levels in 'Betadine LMW' patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Serum iodine levels in control patients
Number of subjects: 75
Study: 30539285

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 1g
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Topical fibrin sealant (FS) 10 ml
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual haemostasis (Control)
Number of subjects: 158
Study: 27986480

Group type: EXPERIMENTAL
Intervention: vonapanitase 10 μg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: vonapanitase 30 μg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 26306970

Group type: EXPERIMENTAL
Intervention: 1.5 mM calcium bath
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1.25 mM calcium bath
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both calcium baths
Number of subjects: 26
Study: 23902670

Group type: EXPERIMENTAL
Intervention: Personalized written asthma action plan (WAAP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care (no WAAP)
Number of subjects: 91
Study: 21063689

Group type: EXPERIMENTAL
Intervention: Visual stimuli presented at the same spatial location as the pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimuli presented at a different spatial location than the pain
Number of subjects: 0
Study: 19143951

Group type: EXPERIMENTAL
Intervention: One parent present
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two parents present
Number of subjects: 0
Study: 17695214

Group type: EXPERIMENTAL
Intervention: 150 mg of cyclamate and 22.5 mg of saccharine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 15147226

Group type: EXPERIMENTAL
Intervention: Alcohol gel as an adjunct to handwashing
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group (standard hand hygiene unit)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Experimental group (alcohol gel with handwashing)
Number of subjects: 253
Study: 11799282

Group type: EXPERIMENTAL
Intervention: Laser fluorescence (LF) system (DIAGNOdent)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Visual caries scoring system
Number of subjects: 170
Study: 9579432

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 905

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 905
Study: 8087484

Group type: EXPERIMENTAL
Intervention: Mechanical injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hand injection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 2675668

Group type: EXPERIMENTAL
Intervention: Succinylcholine injected at different speeds (20 mg/s, 8 mg/s, 4 mg/s, 2 mg/s, 1 mg/s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Succinylcholine injected at different speeds
Number of subjects: 60
Study: 788751

Group type: EXPERIMENTAL
Intervention: Oral indoramin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous indoramin
Number of subjects: 0
Study: 31303153

Group type: EXPERIMENTAL
Intervention: Thrombectomy in direct patients
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Thrombectomy in transfer patients
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 206
Study: 29798346

Group type: EXPERIMENTAL
Intervention: Observation group (patients with nasal local allergy symptoms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Allergic Rhinitis (AR) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy volunteers group
Number of subjects: 60
Study: 26461821

Group type: EXPERIMENTAL
Intervention: Crisaborole topical ointment, 2%
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 25
Study: 22771085

Group type: EXPERIMENTAL
Intervention: Traditional alar base cinch suture (Group I)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Trans-septal alar base cinch suture (Group II)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison between Group I and Group II
Number of subjects: 62
Study: 21810253

Group type: EXPERIMENTAL
Intervention: Tailored activity pacing intervention led by occupational therapists
Number of subjects: 0

Group type: COMPARATOR
Intervention: General activity pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored activity pacing intervention
Number of subjects: 0
Study: 19902498

Group type: EXPERIMENTAL
Intervention: Bayesian multivariate model for spatial binary data using random effects autologistic regression
Number of subjects: 0
Study: 16920656

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: NRT plus a behavioral intervention
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (highly educated patients)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (coronary artery disease, low education)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Subgroup analysis (peripheral arterial disease, low nicotine dependency)
Number of subjects: 346
Study: 15580167

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 12
Study: 11743836

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 536

Group type: COMPARATOR
Intervention: Omalizumab (all dosages)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 9400905

Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg twice daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow-release twice daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg twice daily)
Number of subjects: 44
Study: 8101300

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 mg twice daily)
Number of subjects: 948

Group type: COMPARATOR
Intervention: Aspirin (50 mg per day)
Number of subjects: 948

Group type: COMPARATOR
Intervention: Oral anticoagulants (desired prothrombin time range 2.8-4.8 international normalised ratio)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 948

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 948

Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 948
Study: 6875209

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (400 mg/day for one month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31794163

Group type: EXPERIMENTAL
Intervention: Piezocision-assisted flapless corticotomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no piezocision)
Number of subjects: 42
Study: 28872915

Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 27470506

Group type: EXPERIMENTAL
Intervention: Overall adherence to the CONSORT for Abstracts checklist
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Adherence rate for The Lancet
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Adherence rate for NEJM
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Adherence rates to 8 checklist items
Number of subjects: 463
Study: 24401481

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ologen™ implant (OLO)
Number of subjects: 30
Study: 22615118

Group type: EXPERIMENTAL
Intervention: Liberal sexual attitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High situational risk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low situational risk
Number of subjects: 0
Study: 18785052

Group type: EXPERIMENTAL
Intervention: Multi-grains bread (M-Grains)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wholemeal bread with oatmeal (WM-Oat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wholemeal bread (WM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White bread (WB)
Number of subjects: 12
Study: 17503753

Group type: EXPERIMENTAL
Intervention: Dietary uridine supplement (36 g three times a day for 10 consecutive days/month)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16530147

Group type: EXPERIMENTAL
Intervention: Continuous reminders (as needed)
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Limited reminders (up to 3)
Number of subjects: 1662

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1662
Study: 15474756

Group type: EXPERIMENTAL
Intervention: E2 levels >= 20 pmol/l
Number of subjects: 345

Group type: COMPARATOR
Intervention: E2 levels < 20 pmol/l
Number of subjects: 345
Study: 10776469

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cefuroxime (750 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg i/v post operatively, 12 hourly for 2 days followed by oral 500 mg twice daily for 3 days), n = 35
Number of subjects: 155

Group type: COMPARATOR
Intervention: No antibiotic, n = 30
Number of subjects: 155
Study: 8755854

Group type: EXPERIMENTAL
Intervention: Intermittent peritoneal dialysis
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both interventions (HD and IPD)
Number of subjects: 33
Study: 1655220

Group type: EXPERIMENTAL
Intervention: Edatrexate (10‐EdAM) 80 mg/m2, Cyclophosphamide 800 mg/m2, Cisplatin 80 mg/m2 on day 1, repeated every 3 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Edatrexate (10‐EdAM) 70 mg/m2, Cyclophosphamide 700 mg/m2, Cisplatin 70 mg/m2 on day 1, repeated every 3 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Major response
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reduced dose schedule
Number of subjects: 32
Study: 6304513

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 X 10(6) units intramuscularly before transplant, then three times a week for six weeks and twice a week for eight weeks, total of 102 X 10(6) units)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (given intramuscularly before transplant and following the same schedule as interferon)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Interferon-alpha and Placebo
Number of subjects: 42
Study: 31401899

Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar to infliximab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infliximab RMP (reference medicinal product)
Number of subjects: 0
Study: 27778642

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25730630

Group type: EXPERIMENTAL
Intervention: Temptation to drink (TTD)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Purpose in life (PIL)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Longitudinal associations between TTD and PIL
Number of subjects: 1726
Study: 23949057

Group type: EXPERIMENTAL
Intervention: Functional-rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive-rTMS
Number of subjects: 12
Study: 21480966

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional diabetic diet
Number of subjects: 74
Study: 20025679

Group type: EXPERIMENTAL
Intervention: Low-dose i.v. iron therapy (LD-IVIT) - <or=50 mg/week of iron sucrose
Number of subjects: 119

Group type: COMPARATOR
Intervention: Oral iron therapy (OIT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low-dose i.v. iron therapy (LD-IVIT)
Number of subjects: 119
Study: 16542286

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg infusion every 6 h
Number of subjects: 200

Group type: COMPARATOR
Intervention: CIM 400 mg infusion every 12 h
Number of subjects: 200

Group type: COMPARATOR
Intervention: Omeprazole 40 mg infusion every 12 h
Number of subjects: 200
Study: 12767502

Group type: EXPERIMENTAL
Intervention: Intrathecal triamcinolone acetonide (TCA) administration (6 administrations every third day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continued intrathecal TCA treatment (1 injection every 6 to 12 weeks)
Number of subjects: 36
Study: 10930692

Group type: EXPERIMENTAL
Intervention: DTP-IPV//PRP-T
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: DTP//PRP-T+OPV
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: DTP+PRP-T+OPV
Number of subjects: 252
Study: 9379341

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus melatonin (20 mg/day orally in the evening)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin 20 mg/m2/day i.v. for 3 days and etoposide 100 mg/m2/day i.v. for 3 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus melatonin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 70
Study: 8268648

Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF) with constant dialysate Na (140 mEq/L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF) with varying dialysate Na (150 mEq/L in the first hour, 142 in the second, and 137 in the third)
Number of subjects: 10
Study: 3890131

Group type: EXPERIMENTAL
Intervention: L-carnitine administration (2 g i.v. three times weekly for 6 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study: 31409331

Group type: EXPERIMENTAL
Intervention: T33 (0.1 mg/mL, 0.5 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: T33 (2.5 mg/mL, 5 mg/mL, 10 mg/mL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: T33 (200 mg/kg and 600 mg/kg)
Number of subjects: 3
Study: 29036711

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 2074

Group type: COMPARATOR
Intervention: Control group (non-ECT)
Number of subjects: 2074
Study: 27402551

Group type: EXPERIMENTAL
Intervention: ASSIST administered via ACASI
Number of subjects: 502